In advance of World AIDS Day on Dec 1, the US Centers for Disease Control and Prevention highlighted a survey suggesting that 34% of primary care doctors and nurses in the USA were unaware that pre-exposure prophylaxis (PrEP) can prevent HIV infection. Evidence has shown that daily emtricitabine-tenofovir could prevent up to 92% of HIV infections, and this treatment is recommended in the USA for high-risk groups, including some men who have sex with men and injection drug users. The urgent need for broad awareness, provision, and use of PrEP and other preventive interventions is illustrated by the 2 million new HIV infections that are anticipated, worldwide, each year. On Nov 23 came the welcome announcement that France would shortly become the first European country to provide PrEP free of charge to people at high risk of HIV infection.
UNAIDS released its report, On the Fast-Track to end AIDS by 2030: Focus on location and population, on Nov 24. Here the agenda was to address the needs of the total estimated HIV-infected population of 36·9 million people, with about 1·2 million AIDS-related deaths having occurred in 2014. Provision of antiretroviral treatment had reached a total of 15 million people by March, 2015, with substantial treatment scale-up planned. Refinement of prevention and treatment programmes to individual country contexts will target a situation in which 90% of people with HIV are aware of their status, 90% of diagnosed people are treated, and 90% of those treated achieve viral suppression.
In repositioning the HIV/AIDS response within the Sustainable Development Goals framework, UNAIDS recognises the synergy between development and disease programmes. Implicit in the goal of ending the AIDS epidemic by 2030 along with specific targets, however, is the work that remains to control the spread of HIV and diminish AIDS deaths. Substantial challenges exist for key subpopulations such as women and adolescent girls, and transgender people, especially in settings where stigma and other obstacles prevail. This disease-specific approach to health intertwined with development merits both strong support and continued scrutiny. 
